補è¬äŒç€ŸSupernus PharmaceuticalsãããŠãããæ²»çã«çšããããã©ããŒã(topiramate)ã®æ°è¬ã§ããã1æ¥1åæäžã§åŸæŸæ§ã®é«ãTrokendi XRã®FDAæ¿èªãåããŸãããå瀟ã¯æ°é±é以å ã«è¬å±ã§è²©å£²ããããšãäºå®ããŠããŸãã
ãæ¿èªäžã®å 容ã¯ãFDAãç³è«ã審æ»ããæ¿èªæžã¿ã®è¡šç€ºã«ãã䜿çšæ¹æ³ã«ãããTrokendi XRã®æå¹æ§ã2013幎8æ16æ¥ã«èªãããšãããã®ã§ãããFDAã¯ç¹å®ã®å°å 察象詊éšæ¡ä»¶ãå é€ããããã«ãæéã2019幎ãšããåžè²©åŸã®(å°å ã察象ãšãã)è¬ç©åæ 調æ»ãšãããã«ç¶ã2025幎ã®èšåºè©äŸ¡ã®å»¶æãèš±å¯ããŸããã
Trokendi XRã®èªå¯ã¯Supernus瀟ãšãã®æ ªäž»ããããŠãŠãããæ£è ã«ãšã£ãŠéåžžã«åã°ããç¥ããã§ããããã«å瀟ã¯Trokendi XRãšOxtellar XRã®çºå£²ãç®æããŠããŸãã
Trokendi XRã«ã€ããŠ
Trokendi XRã¯ã匷çŽã»é代æ§çºäœ(tonic-clonic seizures)ãåãã10æ³ä»¥äžã®æ£è ã察象ãšããåæã®åå€çæ³(initial monotherapy)ãããã³ã¬ããã¯ã¹ã»ã¬ã¹ããŒçå矀(Lennox-Gastaut syndrome)é¢é£ã®çºäœãåãã6æ³ä»¥äžã®æ£è ã察象ãšããè£å©çæ³(adjunctive therapy)ã§çšããæãŠãããè¬(AED)ã§ããåè¬ã¯25mgã50mgã100mgãããã³200mgã®åŸæŸã«ãã»ã«ã§ã®äœ¿çšã«ãªããŸãã